|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 405/14 | |
| C07D 403/04 | |||
| C07D 405/04 | |||
| C07D 239/42 | |||
| A61K 31/506 | |||
| A61P 25/00 |
| (11) | Patento numeris | 2909201 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 13785389.1 |
| Europos patento paraiškos padavimo data | 2013-10-21 | |
| (97) | Europos patento paraiškos paskelbimo data | 2015-08-26 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-02-22 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2013/071947 |
| Data | 2013-10-21 |
| (87) | Numeris | WO 2014/064038 |
| Data | 2014-05-01 |
| (30) | Numeris | Data | Šalis |
| 201261716824 P | 2012-10-22 | US | |
| 201361777114 P | 2013-03-12 | US |
| (72) |
HAUPT, Andreas, DE
DINGES, Jürgen, US
UNGER, Liliane, DE
WICKE, Karsten, DE
VAN WATERSCHOOT, Robert, CH
MITTELSTADT, Scott, US
DRESCHER, Karla, DE
RELO, Ana, DE
|
| (73) |
AbbVie Inc.,
1 North Waukegan Road, North Chicago, IL 60064,
US
AbbVie Deutschland GmbH & Co. KG, Mainzer Strasse 81, 65189 Wiesbaden, DE |
| (54) | ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR |
| ACYLAMINOCYCLOALKYL COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF DOPAMINE D3 RECEPTOR |